Will Immunotherapy Shift Treatment Balance for Borderline Resectable Stage III NSCLC? (BMIC-014)
Автор: BeaconMedIC
Загружено: 2017-11-10
Просмотров: 54
Описание:
Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
Visit http://BeaconMedIC.com for more media & information.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: